Imricor Medical Systems (ASX:IMR) reported an 840% year-on-year surge to AU$255,000 in its consumables revenue for the fourth quarter of 2024, according to a Thursday filing with the Australian bourse.
Total revenue reached AU$280,000, excluding the company's first capital sale in Qatar. The sale will be recognized in future quarters upon installation, per the filing.
Cash and cash equivalents at the end of the fourth quarter stood at $15.7 million.
The medical device maker's shares rose past 3% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.